Search
Displaying 321–330 of 790 for “retinitis clinical trial”
-
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Research NewsProof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
FDA Wins Case against Stem-Cell Clinic that Blinded Patients with Bogus Treatment
Research NewsA federal court ruled that the FDA has regulatory authority over these stem-cell procedures and the power to halt them.
-
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
In the PressThe Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
Clinical Research Fellowship Award (CRFA)
Objective/Goal: The program will provide funding for post-residency clinical fellowships in inherited orphan retinal degenerations. The goal is to increase the number of clinician-scientists with expertise and commitment to provided clinical care to patients with inherited orphan retinal degenerations. This program supports up to three post-residency clinicians for one (1) year. $65,000/year
-
Belite Bio Submits New Drug Application to FDA for its Stargardt Treatment
Research NewsTinlarebant becomes first Stargardt treatment submitted to FDA for approval
-
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
Research NewsThe companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
Life as a Teen with Retinitis Pigmentosa
Beacon StoriesAt a mere 15 years old, Ava Ruggiero’s world shifted when she received a diagnosis of retinitis pigmentosa. As Ava continues to find balance as a student and athlete, she discusses the challenges of navigating her diagnosis alongside her parents, Joseph and Stephanie.
-
New Bipartisan Legislation Introduced to Boost Clinical Research for Treatments and Cures
Research NewsThe bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including eye diseases.
-
Release Date: June 5, 2020 Expiration Date: May 29, 2023
This activity offers CE credit for: a. Physicians (CME) b. Optometrists (COPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.
